Hikma Pharmaceuticals's ROE % for the quarter that ended in Dec. 2025 was 12.79%. Hikma Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2025 was 1.78.
Hikma Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 7.19%.
Hikma Pharmaceuticals ROE % Adjusted to Book Value Related Terms
Hikma Pharmaceuticals ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals ROE % Adjusted to Book Value Chart
HKMPF vs ZTS, UTHR, VTRS: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 7.19% mean?
Hikma Pharmaceuticals (HKMPF) has a ROE % Adjusted to Book Value of 7.19% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Hikma Pharmaceuticals and its competitors.
Is Hikma Pharmaceuticals' ROE % Adjusted to Book Value too high?
Hikma Pharmaceuticals' current ROE % Adjusted to Book Value is 7.19%. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' ROE % Adjusted to Book Value compare to ZTS and UTHR?
Hikma Pharmaceuticals' ROE % Adjusted to Book Value of 7.19% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Hikma Pharmaceuticals and its competitors. Hikma Pharmaceuticals's current ROE % Adjusted to Book Value is 7.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $26.53, compared to a current price of $20.12 — trading 24.2% below its estimated fair value. The current ROE % Adjusted to Book Value is 7.19%. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current ROE % Adjusted to Book Value is 7.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $20.12 is trading 24.2% below its estimated GF Value™ of $26.53.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
ROE % Adjusted to Book Value: 7.19%
GF Value™: $26.53 vs. price of $20.12 (24.2% below fair value)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score
Get the complete analysis for HKMPF
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
